Abstract:

The aim of the study was to assess effectiveness and safety of ioversol (Optiray). The contrast media used for angiography and endovascular interventions in 286 patients with coronary disease, peripheral atherosclerosis, liver and biliary disease, hysteromyoma etal. Optiray provided good visualization in 100% of cases at all vascular territories; it did not cause significant hemodynamic changes and was shown to have low allergenic capacity. As a rule, Optiray also did not affect aminotransferases serum concentrations or renal function, but in 1,4% of patients, in preexisting renal function impairment or known risk factors (diabetes, arterial hypertension) a rise of blood creatinine level was seen.

The results allow the authors to conclude that Optiray (Ioversol) satisfies all the requirements for modern contrast media. 

Reference

1.     Сергеев П.В., Cвиридов Н.К., ШимановскийН.Л. Контрастные средства. М. 1993; 256.

2.     Сергеев П.В., Юдин А.Л., Поляев Ю.А.,Шимановский Н.Л. Разработка контрастно-диагностических средств для внутрисосудистого введения: от первых опытов донаших дней. Вестник рентгенологии и радиологии. 2002; 1: 48-61.

3.     Morris T.W. X-ray contrast media. Wherearewe now and where are we going? Radiology.1993; 188: 11-16.

4.     Floriani I.E., Ciceri M.A., Torri V.A., TinazziA.M., Jahn, H.S., Noseda A.M. ClinicalProfile of Ioversol: A Metaanalysis of 57 Randomized, Double-Blind Clinical Trials. Invest.Radiology. 1996; 31 (8): 479-491.

5.     Schild H.H., Kuhl C.K., Hubner-Steiner U.A., Bohm I.M. Adverse Events after Unenhanced and Monomeric and Dimeric Contrast-enhanced CT: A Prospective Randomized Controlled Trial. Radiology. 2006; 240: 56-64.

6.     Ralston W. The acute and subacute toxicity ofioversol (Optiray) in laboratory animals.Invest. Radiology. 1989; 24 (2): 231-240.

7.     Hosoya T., Yamaguchi K., Akutsu T. et al.Delayed adverse reactions to iodinated contrast media and their risk factors. Radiat. Med.2000; 18: 39-45.

8.     Stacul F., Cova M., Assante M. et al.Comparison between the efficacy of dimericand monomeric non-ionic contrast media(iodixanol vs iopromide) in urography inpatients with mild to moderate renal insufficiency. Brit.J. Radiol. 1998; 71: 918-922.

9.     Enzweiler C.N., Hohn S.A., Lembcke A.E. etal. Contrast enhancement in electron beamtomography of the heart: comprasion of amonomeric and a dimeric iodinated contrast agent in 59 patients. ActaRadiol. 2006; 13: 95-103.

10.   Lassers E.C., Lyon S.G. Reports of contrastmedia reactions: analysis of data from reports to the U.S. Food and Drug Administrations Radiology. 1997; 203: 605-610.

11.   Bettmann M.A., Heeren T., Greenfield A.,Goudey C. Adverse events with radiographiccontrast agents, results of SCVIR Contrast agents Registry. Radiology. 1997; 203: 611- 620.

12.   Carraro M., Malalan F., Antonione R. et al.Effects of a dimeric vs a monomeric nonioniccontrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur. Radiol. 1998; 8: 144-147.

13.   Deray G., Bagnis C., Jacquiaud C. et al. Renal effects of low and isoosmolar contrast media on renal hemodynamic in normal and ischemicdog kidney. Invest. Radiology. 1999; 34: 1-4.

14.   Hayami I.S., Ishigooka1 M.G., Suzuki1 Y.T., Mitobe K.I. Comparison of the nephrotoxicity between ioversol and iohexol. International Urology and Nephrology. 1996; 3: 615-619.

15.   Misawa M., Sato Y., Hara M. et al. Use of nonionic contrast medium, iopromide (Proscope 370), in pediatric cardiovascular angiography. Nihon ShoniHoshasen Gakkai Zasshi. 2000; 16: 42-44.

16.   Кармазановский Г.Г. «Старое» неионное рентгеноконтрастное вещество иоверсол -«новый игрок» на российском рынке контрастных средств. Медицинская визуализация. 2007; 2: 135-139.

17.   Корниенко В.Н., Пронин И.И., Такуш С.В., Фадеева Л.М. Новые возможности контрастирования в нейрорадологии. Медицинская визуализация. 2006; 6: 126-133.